18F-PSMA-1007 |
18F-PSMA-1007 |
Phase 3 Clinical |
Deutsches Krebsforschungszentrum |
Neoplasms; Prostatic Neoplasms |
Details
|
Gallium-68 PSMA-617 |
225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; Gallium-68-PSMA-617; PSMA-617-[68Ga]; 68Ga-DOTA-PSMA-DKFZ -617 |
Phase 3 Clinical |
Peking Union Medical College Hospital |
Carcinoma, Adenoid Cystic; Prostatic Neoplasms |
Details
|
Fluorine-18-CTT-1057 |
CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 |
Phase 3 Clinical |
Washington University, Cancer Targeted Technology Llc |
Recurrence; Carcinoma, Renal Cell; Prostatic Neoplasms |
Details
|
ITM-24D |
ITM-24D; 68Ga-PSMA-TTM |
Phase 3 Clinical |
ITM Isotope Technologies Munich SE |
Prostatic Neoplasms |
Details
|
18F vipivotide tetraxetan |
18F-PSMA-617; Al18F-PSMA-617 |
Phase 3 Clinical |
Peking Union Medical College Hospital |
Prostatic Neoplasms |
Details
|
64Cu-PSMA I&T |
Copper Cu 64 PSMA I&T; Cu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T |
Phase 3 Clinical |
Curium Us Llc |
Prostatic Neoplasms |
Details
|
Thretide[18F] |
|
Phase 3 Clinical |
Shanghai Lannacheng Biotechnology Co Ltd |
Neoplasms; Prostatic Neoplasms; Diagnostic agents |
Details
|
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) |
|
Phase 3 Clinical |
Clarity Pharmaceuticals Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-DOTA-rosopatamb |
177Lu-DOTA-TLX591-CHO; TLX591 |
Phase 3 Clinical |
Telix Pharmaceuticals Ltd |
Prostatic Neoplasms |
Details
|
[Lu177]-PNT-2002 |
PNT-2002 |
Phase 3 Clinical |
|
Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
Lutetium-177-PSMA-I&T |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Salivary Gland Neoplasms; Carcinoma, Adenoid Cystic; Prostatic Neoplasms |
Details
|
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) |
|
Phase 2 Clinical |
Advanced Accelerator Applications Sa |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-PSMA-R2 |
177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 |
Phase 2 Clinical |
Advanced Accelerator Applications Sa |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
89Zr-DFO-huJ591 |
Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 |
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center |
Prostatic Neoplasms |
Details
|
Nezastomig |
REGN-5678 |
Phase 2 Clinical |
|
Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
225Ac-J591 |
225Ac-DOTA-J591; 225Ac-J591; CONV 01-α |
Phase 2 Clinical |
Cornell University |
Prostatic Neoplasms |
Details
|
ATL-101 |
MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 |
Phase 2 Clinical |
Weill Medical College of Cornell University |
Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung |
Details
|
[131I]MIP-1095 |
1095; [131I]MIP-1095; [131I]MIP-1466 |
Phase 2 Clinical |
Progenics Pharmaceuticals Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
CONV-01-alpha + PSMA I&T |
|
Phase 2 Clinical |
Convergent Therapeutics Inc |
Prostatic Neoplasms |
Details
|
LAVA-1207 |
LAVA-1207 |
Phase 2 Clinical |
Vu University Medical Center, Lava Therapeutics NV |
Prostatic Neoplasms, Castration-Resistant |
Details
|
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Neoplasms |
Details
|
[225Ac]Ac-PSMA-R2 |
[225Ac]Ac-PSMA-R2 |
Phase 2 Clinical |
Novartis Pharma Ag |
Prostatic Neoplasms, Castration-Resistant |
Details
|
177Lu-PSMA |
177Lu-PSMA |
Phase 2 Clinical |
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori |
Carcinoma, Renal Cell; Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis |
Details
|
[177Lu]JH020002 |
Lu 177 JH020002; [177Lu]JH020002; 177-Lu JH-020002 |
Phase 2 Clinical |
Bivision Biomedical Technology (Nanjing) Co Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
[177Lu]Lu-XT033 |
[177Lu]Lu-XT033 |
Phase 2 Clinical |
|
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-HTK03170 |
177Lu-HTK03170 |
Phase 2 Clinical |
British Columbia Cancer Agency |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
Ga-68-NGUL |
|
Phase 2 Clinical |
Cellbion Co Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
bi-4SCAR GD2/PSMA |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Solid tumours |
Details
|
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
bi-4SCAR PSMA/CD70 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Neoplasms |
Details
|
177Lu-rhPSMA-10.1 |
177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu rhPSMA-10.1; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu-rhPSMA-10.1; 177Lu-rhPSMA |
Phase 2 Clinical |
Technical University Munich |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases |
Details
|
Lu-177-DGUL |
PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL |
Phase 2 Clinical |
Cellbion Co Ltd |
Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
TLX-592 |
TLX-592 |
Phase 2 Clinical |
Telix Pharmaceuticals Ltd |
Prostatic Neoplasms |
Details
|
68Ga-PSMA-IRDye |
TLX591-Sx |
Phase 2 Clinical |
Telix Pharmaceuticals Ltd |
Prostatic Neoplasms |
Details
|
REGN-4336 |
REGN-4336 |
Phase 2 Clinical |
|
Prostatic Neoplasms, Castration-Resistant |
Details
|
[177Lu]Ludotadipep |
177Lu-FC705; 177Lu-FC-705 |
Phase 2 Clinical |
Futurechem |
Prostatic Neoplasms, Castration-Resistant |
Details
|
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) |
|
Phase 2 Clinical |
Clarity Pharmaceuticals Ltd |
Prostatic Neoplasms, Castration-Resistant |
Details
|
ARX-517 |
ARX-517; ARX517 |
Phase 2 Clinical |
|
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
OTL-78 |
OTL-78 |
Phase 2 Clinical |
Purdue University, Novartis Pharma Ag |
Prostatic Neoplasms |
Details
|
INO-5401 |
INO-5401 |
Phase 2 Clinical |
Inovio Pharmaceuticals Inc |
Carcinoma, Transitional Cell; Glioblastoma |
Details
|
225 Actinium PSMA-617 |
225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 |
Phase 1 Clinical |
Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa |
Prostatic Neoplasms, Castration-Resistant |
Details
|
JNJ-63898081 |
JNJ-8081; JNJ-63898081 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine |
Neoplasms |
Details
|
P28z-CAR |
P28z-CAR |
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center, United States Department Of Defense |
Prostatic Neoplasms |
Details
|
PSMA-CART cell therapy (Shanghai Bioray Laboratory) |
|
Phase 1 Clinical |
BRL Medicine Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center |
|
Phase 1 Clinical |
Roger Williams Medical Center |
Prostatic Neoplasms |
Details
|
CC-1 |
CC-1 |
Phase 1 Clinical |
University Of Tubingen, German Cancer Research Center (Dkfz) |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell |
Details
|
Acapatamab |
AMG-160 |
Phase 1 Clinical |
Amgen Inc |
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung |
Details
|
177Lu-EB-vipivotide tetraxetan |
177-Lu-EB-PSMA-617 |
Phase 1 Clinical |
Peking Union Medical College Hospital, National Institute For Biomedical Imaging And Bioengineering (Nibib) |
Carcinoma, Renal Cell; Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
[177Lu]-CTT-1403 |
CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 |
Phase 1 Clinical |
Cancer Targeted Technology Llc |
Prostatic Neoplasms |
Details
|
Pelgifatamab corixetan |
BAY-2315497 |
Phase 1 Clinical |
Bayer AG |
Prostatic Neoplasms, Castration-Resistant |
Details
|
161Tb-SibuDAB |
|
Phase 1 Clinical |
University Hospital Basel |
Prostatic Neoplasms, Castration-Resistant |
Details
|
[Ac-225]-PSMA-62 |
[Ac-225]-PSMA-62 |
Phase 1 Clinical |
|
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
JNJ-9401 |
JNJ-9401 |
Phase 1 Clinical |
Xencor Inc |
Prostatic Neoplasms |
Details
|
ABBV-969 |
ABBV-969; ABBV969 |
Phase 1 Clinical |
Abbvie Inc, Immunogen Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
JNJ-87189401 |
JNJ-87189401 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms |
Details
|
Actinium-225-macropa-pelgifatamab |
BAY-3546828; BAY3546828 |
Phase 1 Clinical |
Bayer AG |
Prostatic Neoplasms, Castration-Resistant |
Details
|
177Lu-LNC1003 |
177Lu-LNC1003 |
Phase 1 Clinical |
Shanghai Lannacheng Biotechnology Co Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
PSMA-Targeted [In-111]-Labeled Trillium Compound |
|
Phase 1 Clinical |
Ratio Therapeutics Inc |
Prostatic Neoplasms |
Details
|
Autologous T cells therapy(Unicar-Therapy) |
|
Phase 1 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Prostatic Neoplasms |
Details
|
212Pb-NG001 |
212Pb-NG001; AB-001; AB001 |
Phase 1 Clinical |
ARTBIO Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
CART-PSMA cells(Nova Therapeutics) |
|
Phase 1 Clinical |
Nova Therapeutics LLC |
Prostatic Neoplasms |
Details
|
68Ga-labeled NY108 |
68-Ga-labeled NY-108 |
Phase 1 Clinical |
|
Prostatic Neoplasms |
Details
|
JANX-007 |
JANX-007; PSMA-TRACTr |
Phase 1 Clinical |
Janux Therapeutics Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
JNJ-80038114 |
JNJ-80038114 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms |
Details
|
CART-PSMA-TGFbRDN (University of Pennsylvania) |
|
Phase 1 Clinical |
University Of Pennsylvania |
Prostatic Neoplasms |
Details
|
TNB-585 |
TNB-585; AMG-340 |
Phase 1 Clinical |
Teneobio Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
AVC-102 |
AVC-102 |
Phase 1 Clinical |
AvenCell Therapeutics Inc |
Kidney Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
CBP-1018 |
CBP-1018 |
Phase 1 Clinical |
|
Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms |
Details
|
CCW-702 |
CCW-702 |
Phase 1 Clinical |
The Scripps Research Institute Inc, Abbvie Inc |
Prostatic Neoplasms |
Details
|
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) |
|
Phase 1 Clinical |
Sorrento Therapeutics Inc |
Neoplasms |
Details
|
CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics) |
TmPSMA-02 |
Phase 1 Clinical |
University Of Minnesota, University Of Pennsylvania |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-PSMA-0057 |
177Lu-PSMA-0057 |
|
Nanjing First Hospital, Nanjing Medical University |
|
Details
|
[68Ga]Ga-PSMA-D5 |
[68Ga]Ga-PSMA-D5 |
|
Anhui Provincial Hospital |
|
Details
|
18F-PSMA-1007 |
18F-PSMA-1007 |
Phase 3 Clinical |
Deutsches Krebsforschungszentrum |
Neoplasms; Prostatic Neoplasms |
Details
|
Gallium-68 PSMA-617 |
225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; Gallium-68-PSMA-617; PSMA-617-[68Ga]; 68Ga-DOTA-PSMA-DKFZ -617 |
Phase 3 Clinical |
Peking Union Medical College Hospital |
Carcinoma, Adenoid Cystic; Prostatic Neoplasms |
Details
|
Fluorine-18-CTT-1057 |
CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 |
Phase 3 Clinical |
Washington University, Cancer Targeted Technology Llc |
Recurrence; Carcinoma, Renal Cell; Prostatic Neoplasms |
Details
|
ITM-24D |
ITM-24D; 68Ga-PSMA-TTM |
Phase 3 Clinical |
ITM Isotope Technologies Munich SE |
Prostatic Neoplasms |
Details
|
18F vipivotide tetraxetan |
18F-PSMA-617; Al18F-PSMA-617 |
Phase 3 Clinical |
Peking Union Medical College Hospital |
Prostatic Neoplasms |
Details
|
64Cu-PSMA I&T |
Copper Cu 64 PSMA I&T; Cu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T |
Phase 3 Clinical |
Curium Us Llc |
Prostatic Neoplasms |
Details
|
Thretide[18F] |
|
Phase 3 Clinical |
Shanghai Lannacheng Biotechnology Co Ltd |
Neoplasms; Prostatic Neoplasms; Diagnostic agents |
Details
|
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) |
|
Phase 3 Clinical |
Clarity Pharmaceuticals Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-DOTA-rosopatamb |
177Lu-DOTA-TLX591-CHO; TLX591 |
Phase 3 Clinical |
Telix Pharmaceuticals Ltd |
Prostatic Neoplasms |
Details
|
[Lu177]-PNT-2002 |
PNT-2002 |
Phase 3 Clinical |
|
Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
Lutetium-177-PSMA-I&T |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Salivary Gland Neoplasms; Carcinoma, Adenoid Cystic; Prostatic Neoplasms |
Details
|
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) |
|
Phase 2 Clinical |
Advanced Accelerator Applications Sa |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-PSMA-R2 |
177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 |
Phase 2 Clinical |
Advanced Accelerator Applications Sa |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
89Zr-DFO-huJ591 |
Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 |
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center |
Prostatic Neoplasms |
Details
|
Nezastomig |
REGN-5678 |
Phase 2 Clinical |
|
Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
225Ac-J591 |
225Ac-DOTA-J591; 225Ac-J591; CONV 01-α |
Phase 2 Clinical |
Cornell University |
Prostatic Neoplasms |
Details
|
ATL-101 |
MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 |
Phase 2 Clinical |
Weill Medical College of Cornell University |
Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung |
Details
|
[131I]MIP-1095 |
1095; [131I]MIP-1095; [131I]MIP-1466 |
Phase 2 Clinical |
Progenics Pharmaceuticals Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
CONV-01-alpha + PSMA I&T |
|
Phase 2 Clinical |
Convergent Therapeutics Inc |
Prostatic Neoplasms |
Details
|
LAVA-1207 |
LAVA-1207 |
Phase 2 Clinical |
Vu University Medical Center, Lava Therapeutics NV |
Prostatic Neoplasms, Castration-Resistant |
Details
|
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Neoplasms |
Details
|
[225Ac]Ac-PSMA-R2 |
[225Ac]Ac-PSMA-R2 |
Phase 2 Clinical |
Novartis Pharma Ag |
Prostatic Neoplasms, Castration-Resistant |
Details
|
177Lu-PSMA |
177Lu-PSMA |
Phase 2 Clinical |
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori |
Carcinoma, Renal Cell; Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis |
Details
|
[177Lu]JH020002 |
Lu 177 JH020002; [177Lu]JH020002; 177-Lu JH-020002 |
Phase 2 Clinical |
Bivision Biomedical Technology (Nanjing) Co Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
[177Lu]Lu-XT033 |
[177Lu]Lu-XT033 |
Phase 2 Clinical |
|
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-HTK03170 |
177Lu-HTK03170 |
Phase 2 Clinical |
British Columbia Cancer Agency |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
Ga-68-NGUL |
|
Phase 2 Clinical |
Cellbion Co Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
bi-4SCAR GD2/PSMA |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Solid tumours |
Details
|
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
bi-4SCAR PSMA/CD70 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Neoplasms |
Details
|
177Lu-rhPSMA-10.1 |
177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu rhPSMA-10.1; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu-rhPSMA-10.1; 177Lu-rhPSMA |
Phase 2 Clinical |
Technical University Munich |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases |
Details
|
Lu-177-DGUL |
PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL |
Phase 2 Clinical |
Cellbion Co Ltd |
Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
TLX-592 |
TLX-592 |
Phase 2 Clinical |
Telix Pharmaceuticals Ltd |
Prostatic Neoplasms |
Details
|
68Ga-PSMA-IRDye |
TLX591-Sx |
Phase 2 Clinical |
Telix Pharmaceuticals Ltd |
Prostatic Neoplasms |
Details
|
REGN-4336 |
REGN-4336 |
Phase 2 Clinical |
|
Prostatic Neoplasms, Castration-Resistant |
Details
|
[177Lu]Ludotadipep |
177Lu-FC705; 177Lu-FC-705 |
Phase 2 Clinical |
Futurechem |
Prostatic Neoplasms, Castration-Resistant |
Details
|
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) |
|
Phase 2 Clinical |
Clarity Pharmaceuticals Ltd |
Prostatic Neoplasms, Castration-Resistant |
Details
|
ARX-517 |
ARX-517; ARX517 |
Phase 2 Clinical |
|
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
OTL-78 |
OTL-78 |
Phase 2 Clinical |
Purdue University, Novartis Pharma Ag |
Prostatic Neoplasms |
Details
|
INO-5401 |
INO-5401 |
Phase 2 Clinical |
Inovio Pharmaceuticals Inc |
Carcinoma, Transitional Cell; Glioblastoma |
Details
|
225 Actinium PSMA-617 |
225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 |
Phase 1 Clinical |
Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa |
Prostatic Neoplasms, Castration-Resistant |
Details
|
JNJ-63898081 |
JNJ-8081; JNJ-63898081 |
Phase 1 Clinical |
Johnson & Johnson Innovative Medicine |
Neoplasms |
Details
|
P28z-CAR |
P28z-CAR |
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center, United States Department Of Defense |
Prostatic Neoplasms |
Details
|
PSMA-CART cell therapy (Shanghai Bioray Laboratory) |
|
Phase 1 Clinical |
BRL Medicine Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center |
|
Phase 1 Clinical |
Roger Williams Medical Center |
Prostatic Neoplasms |
Details
|
CC-1 |
CC-1 |
Phase 1 Clinical |
University Of Tubingen, German Cancer Research Center (Dkfz) |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell |
Details
|
Acapatamab |
AMG-160 |
Phase 1 Clinical |
Amgen Inc |
Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung |
Details
|
177Lu-EB-vipivotide tetraxetan |
177-Lu-EB-PSMA-617 |
Phase 1 Clinical |
Peking Union Medical College Hospital, National Institute For Biomedical Imaging And Bioengineering (Nibib) |
Carcinoma, Renal Cell; Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
[177Lu]-CTT-1403 |
CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 |
Phase 1 Clinical |
Cancer Targeted Technology Llc |
Prostatic Neoplasms |
Details
|
Pelgifatamab corixetan |
BAY-2315497 |
Phase 1 Clinical |
Bayer AG |
Prostatic Neoplasms, Castration-Resistant |
Details
|
161Tb-SibuDAB |
|
Phase 1 Clinical |
University Hospital Basel |
Prostatic Neoplasms, Castration-Resistant |
Details
|
[Ac-225]-PSMA-62 |
[Ac-225]-PSMA-62 |
Phase 1 Clinical |
|
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
JNJ-9401 |
JNJ-9401 |
Phase 1 Clinical |
Xencor Inc |
Prostatic Neoplasms |
Details
|
ABBV-969 |
ABBV-969; ABBV969 |
Phase 1 Clinical |
Abbvie Inc, Immunogen Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
JNJ-87189401 |
JNJ-87189401 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms |
Details
|
Actinium-225-macropa-pelgifatamab |
BAY-3546828; BAY3546828 |
Phase 1 Clinical |
Bayer AG |
Prostatic Neoplasms, Castration-Resistant |
Details
|
177Lu-LNC1003 |
177Lu-LNC1003 |
Phase 1 Clinical |
Shanghai Lannacheng Biotechnology Co Ltd |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
PSMA-Targeted [In-111]-Labeled Trillium Compound |
|
Phase 1 Clinical |
Ratio Therapeutics Inc |
Prostatic Neoplasms |
Details
|
Autologous T cells therapy(Unicar-Therapy) |
|
Phase 1 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Prostatic Neoplasms |
Details
|
212Pb-NG001 |
212Pb-NG001; AB-001; AB001 |
Phase 1 Clinical |
ARTBIO Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
CART-PSMA cells(Nova Therapeutics) |
|
Phase 1 Clinical |
Nova Therapeutics LLC |
Prostatic Neoplasms |
Details
|
68Ga-labeled NY108 |
68-Ga-labeled NY-108 |
Phase 1 Clinical |
|
Prostatic Neoplasms |
Details
|
JANX-007 |
JANX-007; PSMA-TRACTr |
Phase 1 Clinical |
Janux Therapeutics Inc |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
JNJ-80038114 |
JNJ-80038114 |
Phase 1 Clinical |
Janssen Research & Development Llc |
Prostatic Neoplasms |
Details
|
CART-PSMA-TGFbRDN (University of Pennsylvania) |
|
Phase 1 Clinical |
University Of Pennsylvania |
Prostatic Neoplasms |
Details
|
TNB-585 |
TNB-585; AMG-340 |
Phase 1 Clinical |
Teneobio Inc |
Prostatic Neoplasms, Castration-Resistant |
Details
|
AVC-102 |
AVC-102 |
Phase 1 Clinical |
AvenCell Therapeutics Inc |
Kidney Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
CBP-1018 |
CBP-1018 |
Phase 1 Clinical |
|
Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms |
Details
|
CCW-702 |
CCW-702 |
Phase 1 Clinical |
The Scripps Research Institute Inc, Abbvie Inc |
Prostatic Neoplasms |
Details
|
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) |
|
Phase 1 Clinical |
Sorrento Therapeutics Inc |
Neoplasms |
Details
|
CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics) |
TmPSMA-02 |
Phase 1 Clinical |
University Of Minnesota, University Of Pennsylvania |
Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms |
Details
|
177Lu-PSMA-0057 |
177Lu-PSMA-0057 |
|
Nanjing First Hospital, Nanjing Medical University |
|
Details
|
[68Ga]Ga-PSMA-D5 |
[68Ga]Ga-PSMA-D5 |
|
Anhui Provincial Hospital |
|
Details
|